{
  "docId": "019de513-bbaf-7632-8c51-2e65d00dc762",
  "docSlug": "d61504792622527e2ff1c803565a1f5e",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 42 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 42,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 48,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de513-bbaf-7632-8c51-2e65d00dc762/10",
  "deckHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762",
  "deckJsonHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762.json",
  "deckAnchorHref": "/decks/019de513-bbaf-7632-8c51-2e65d00dc762#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.602,
        "x": 0.149,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes.\n2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n3. On a proforma basis after giving effect to the IPO.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13f62d8e-805b-4805-9343-883aa023614f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.69,
        "w": 0.85,
        "x": 0.075,
        "y": 0.168
      },
      "kind": "table",
      "text": "Bausch + Lomb 2Q22 2Q21 Reported Change Constant Currency2 Organic Change2 Vision Care Revenue $589M $556M 6% 11% 11% Surgical Revenue $184M $185M (1%) 5% 7% Ophthalmic Pharmaceuticals Revenue $168M $193M (13%) (10%) (10%) Total Revenue $941M $934M 1% 6% 6% Gross Profit $498M $488M 2% 7% Gross Margin 52.9% 52.2% 70 bps R&D $75M $71M (6%) (8%) R&D percent of Revenues 8.0% 7.6% SG&A $368M $358M (3%) (7%) SG&A percent of Revenues 39.1% 38.3% Operating Income $56M $58M (3%) 7% Depreciation $34M $34M 0% 6% Stock Based Compensation $11M $15M (27%) (27%) Net Income $5M $44M (89%) (66%) Net Income Margin 0.5% 4.7% EPS3 $0.01 $0.13",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2af29b83-ee6a-4f21-a35e-27b1baeb7c41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.027,
        "w": 0.406,
        "x": 0.048,
        "y": 0.048
      },
      "kind": "title",
      "text": "Total Bausch + Lomb P&L¹ (GAAP)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "772824b5-2062-4e6b-8fcb-3131328adedf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "0893e56b-0769-4382-a0b2-590412f35bd2",
      "evidence": "table/data: Bausch + Lomb 2Q22 2Q21 Reported Change Constant Currency2 Organic Change2 Vision Care Revenue $589M $556M 6% 11% 11% Surgical Revenue $184M $185M (1%) 5% 7% Ophthalmic Pharmaceuticals Revenue $168M $193M (13",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d0820f93-74dc-4006-a0cc-2e2499a07167",
      "evidence": "The loop opens on slide 6 and closes on slide 15, showcasing the company's opportunities",
      "position": 0,
      "objective": "Highlighting the benefits of a standalone Bausch + Lomb",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}